COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Article view: 261

Article download: 105

IP Journal of Surgery and Allied Sciences

Myoepithelioma of parotid gland - A rare entity

Full Text PDF Share on Facebook Share on Twitter

Case Report

Author Details : Rajesh B Dhirawani, Jay Taank, Irfan Zunzani*, Sauvik Singha

Volume : 1, Issue : 2, Year : 2020

Article Page : 42-45

Suggest article by email


Myoepithelioma is a rare salivary gland neoplasm. It is seen around 1-1.5% among all salivary gland. Parotid gland is the most common site of occurrence. The second most common site is palatal minor salivary glands. This neoplasm came into literature long back but the histopathologic picture doesn’t seem to be well characterized. Many authors attribute the complexity of this neoplasm. The myoepithelial component that is seen between the basement membrane. It is also seen in the basal plasma membrane of acinar cells. Traditionally it's been represented that it consists of spindle myoepitheliocytes. Pathologically myoepithelioma is accepted as a specific entity. In this article, we are presenting a case of a 76-year-old male with salivary gland myoepithelioma, an especially rare entity. We have also given a brief description of its clinical and pathologic feature. 

Keywords: Myoepithelioma, Parotid tumor, Salivary gland tumor.

How to cite : Dhirawani R B, Taank J, Zunzani I, Singha S, Myoepithelioma of parotid gland - A rare entity. IP J Surg Allied Sci 2020;1(2):42-45

Copyright © 2020 by author(s) and IP J Surg Allied Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (